Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Connect Biopharma HoldingsCNTB +3.18%7 Receivables Turnover is 13.00 as of Mar. 2026. GuruFocus rates CNTB with a GF Score™ of 7/100. The stock has 3 warning signs investors should review. Among 841 Biotechnology companies, Connect Biopharma Holdings ranks worse than 90.73% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Connect Biopharma Holdings's Revenue for the
three
months ended in Mar. 2026 was $0.17 Mil. Connect Biopharma Holdings's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.01 Mil.
Hence, Connect Biopharma Holdings's Receivables Turnover for the
three
months ended in Mar. 2026 was 13.00.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Connect Biopharma Holdings Receivables Turnover Related Terms
Connect Biopharma Holdings Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNTB vs ENLV, SMNR, MENS: Receivables Turnover Comparison
For the Biotechnology subindustry, Connect Biopharma Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Connect Biopharma Holdings Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Connect Biopharma Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Connect Biopharma Holdings (CNTB) has a Receivables Turnover of 13.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Connect Biopharma Holdings and its competitors. According to the industry distribution chart, Connect Biopharma Holdings ranks #763 out of 841 companies in the Biotechnology industry, placing it in the top 90.7%.
Is Connect Biopharma Holdings' Receivables Turnover too high?
Connect Biopharma Holdings' current Receivables Turnover is 13.00. The Biotechnology industry median Receivables Turnover is 5.29. Connect Biopharma Holdings' value of 13.00 is 145.7% above this industry median. Based on the distribution chart, Connect Biopharma Holdings ranks #763 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Connect Biopharma Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Connect Biopharma Holdings' Receivables Turnover compare to ENLV and SMNR?
According to the Biotechnology industry distribution chart, Connect Biopharma Holdings ranks #763 out of 841 companies for Receivables Turnover. This places Connect Biopharma Holdings in the lower half of its industry. The industry median Receivables Turnover is 5.29. Connect Biopharma Holdings' value of 13.00 is 145.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Connect Biopharma Holdings's current Receivables Turnover of 13.00 is 145.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Connect Biopharma Holdings and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Connect Biopharma Holdings's current Receivables Turnover is 13.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Connect Biopharma Holdings stock overvalued right now?
Connect Biopharma Holdings (CNTB) has a current Receivables Turnover of 13.00. The current Receivables Turnover is 13.00 and 145.7% above the Biotechnology industry median of 5.29. Connect Biopharma Holdings' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Connect Biopharma Holdings (CNTB), the current Receivables Turnover is 13.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
7GF Score
Get the complete analysis for CNTB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTB has been successfully added to your 
